NCT02029443View on ClinicalTrials.gov

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

January 30, 2014

Primary Completion Date

July 15, 2021

Study Completion Date

September 6, 2027

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's SyndromeProlymphocytic Leukemia
Interventions
DRUG

Acalabrutinib

Participants will receive acalabrutinib as stated in the arms' description.

Trial Locations (12)

2215

Research Site, Boston

10021

Research Site, New York

11042

Research Site, New Hyde Park

20132

Research Site, Milan

43210

Research Site, Columbus

76104

Research Site, Fort Worth

84112

Research Site, Salt Lake City

98122

Research Site, Seattle

98405

Research Site, Tacoma

LS9 7TF

Research Site, Leeds

SE5 9RS

Research Site, London

OX3 7LE

Research Site, Oxford

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY